Preoperative endogenous total testosterone predicts prostate cancer progression: results in 580 consecutive patients treated with robot assisted radical prostatectomy for clinically localized disease.

Journal: International urology and nephrology
PMID:

Abstract

PURPOSE: To test the role of endogenous total testosterone (ETT) as a predictor of prostate cancer (PCa) progression in patients treated with robot assisted radical prostatectomy for clinically localized disease.

Authors

  • Antonio Benito Porcaro
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy. drporcaro@yahoo.com.
  • Andrea Panunzio
    Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Emanuele Serafin
    Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Alberto Bianchi
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Sebastian Gallina
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Giovanni Mazzucato
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Stefano Vidiri
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Damiano D'Aietti
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Rossella Orlando
    Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Francesco Ditonno
    Department of Urology, Rush University, Chicago, IL, USA.
  • Francesca Montanaro
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Giulia Marafioti Patuzzo
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Alberto Bailelli
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Francesco Artoni
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Stefano Zecchini Antoniolli
    Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Riccardo Rizzetto
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Matteo Brunelli
    Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Salvatore Siracusano
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Maria Angela Cerruto
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Alessandro Tafuri
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Alessandro Antonelli
    Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, Italy.